(Q42996562)

12 November 2017

Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C. (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

4

1 reference

12 November 2017

R Schvarcz

1

1 reference

12 November 2017

H Glaumann

series ordinal

2

1 reference

12 November 2017

O Reichard

series ordinal

3

1 reference

12 November 2017

language of work or name

1 reference

1 May 1999

1 reference

Journal of Viral Hepatitis

12 November 2017

1 reference

12 November 2017

6

1 reference

12 November 2017

237-242

1 reference

12 November 2017

3

1 reference

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

12 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00156.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00156.X

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00156.X

Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00156.X

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00156.X

Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00156.X

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1999.00156.X

10.1046/J.1365-2893.1999.00156.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference